228 related articles for article (PubMed ID: 33896285)
1. Classification and QSAR models of leukotriene A4 hydrolase (LTA4H) inhibitors by machine learning methods.
Qin R; Wang H; Yan A
SAR QSAR Environ Res; 2021 May; 32(5):411-431. PubMed ID: 33896285
[TBL] [Abstract][Full Text] [Related]
2. SAR and QSAR models of cyclooxygenase-1 (COX-1) inhibitors.
Xi Y; Qin Z; Yan A
SAR QSAR Environ Res; 2018 Oct; 29(10):755-784. PubMed ID: 30274533
[TBL] [Abstract][Full Text] [Related]
3. Development of predictive quantitative structure-activity relationship model and its application in the discovery of human leukotriene A4 hydrolase inhibitors.
Thangapandian S; John S; Son M; Arulalapperumal V; Lee KW
Future Med Chem; 2013 Jan; 5(1):27-40. PubMed ID: 23256811
[TBL] [Abstract][Full Text] [Related]
4. Leukotriene A4 hydrolase as a target for cancer prevention and therapy.
Chen X; Wang S; Wu N; Yang CS
Curr Cancer Drug Targets; 2004 May; 4(3):267-83. PubMed ID: 15134534
[TBL] [Abstract][Full Text] [Related]
5. Identification of Human Leukotriene A4 Hydrolase Inhibitors Using Structure-Based Pharmacophore Modeling and Molecular Docking.
Audat SA; Al-Shar'i NA; Al-Oudat BA; Bryant-Friedrich A; Bedi MF; Zayed AL; Al-Balas QA
Molecules; 2020 Jun; 25(12):. PubMed ID: 32580506
[TBL] [Abstract][Full Text] [Related]
6. Feasibility and physiological relevance of designing highly potent aminopeptidase-sparing leukotriene A4 hydrolase inhibitors.
Numao S; Hasler F; Laguerre C; Srinivas H; Wack N; Jäger P; Schmid A; Osmont A; Röthlisberger P; Houguenade J; Bergsdorf C; Dawson J; Carte N; Hofmann A; Markert C; Hardaker L; Billich A; Wolf RM; Penno CA; Bollbuck B; Miltz W; Röhn TA
Sci Rep; 2017 Oct; 7(1):13591. PubMed ID: 29051536
[TBL] [Abstract][Full Text] [Related]
7. SAR study on inhibitors of GIIA secreted phospholipase A
Zhang S; Li Y; Qin Z; Tu G; Chen G; Yan A
Chem Biol Drug Des; 2019 May; 93(5):666-684. PubMed ID: 30582300
[TBL] [Abstract][Full Text] [Related]
8. Thermodynamic properties of leukotriene A
Wittmann SK; Kalinowsky L; Kramer JS; Bloecher R; Knapp S; Steinhilber D; Pogoryelov D; Proschak E; Heering J
Bioorg Med Chem; 2016 Nov; 24(21):5243-5248. PubMed ID: 27651294
[TBL] [Abstract][Full Text] [Related]
9. Pharmacophore-based virtual screening and Bayesian model for the identification of potential human leukotriene A4 hydrolase inhibitors.
Thangapandian S; John S; Sakkiah S; Lee KW
Eur J Med Chem; 2011 May; 46(5):1593-603. PubMed ID: 21377770
[TBL] [Abstract][Full Text] [Related]
10. Dual anti-inflammatory and selective inhibition mechanism of leukotriene A4 hydrolase/aminopeptidase: insights from comparative molecular dynamics and binding free energy analyses.
Appiah-Kubi P; Soliman ME
J Biomol Struct Dyn; 2016 Nov; 34(11):2418-33. PubMed ID: 26555301
[TBL] [Abstract][Full Text] [Related]
11. Hybrid Receptor-Bound/MM-GBSA-Per-residue Energy-Based Pharmacophore Modelling: Enhanced Approach for Identification of Selective LTA4H Inhibitors as Potential Anti-inflammatory Drugs.
Appiah-Kubi P; Soliman M
Cell Biochem Biophys; 2017 Mar; 75(1):35-48. PubMed ID: 27914004
[TBL] [Abstract][Full Text] [Related]
12. A sensitive fluorigenic substrate for selective in vitro and in vivo assay of leukotriene A4 hydrolase activity.
Poras H; Duquesnoy S; Fournié-Zaluski MC; Ratinaud-Giraud C; Roques BP; Ouimet T
Anal Biochem; 2013 Oct; 441(2):152-61. PubMed ID: 23851339
[TBL] [Abstract][Full Text] [Related]
13. QSAR studies of the bioactivity of hepatitis C virus (HCV) NS3/4A protease inhibitors by multiple linear regression (MLR) and support vector machine (SVM).
Qin Z; Wang M; Yan A
Bioorg Med Chem Lett; 2017 Jul; 27(13):2931-2938. PubMed ID: 28501513
[TBL] [Abstract][Full Text] [Related]
14. Computational models for the classification of mPGES-1 inhibitors with fingerprint descriptors.
Xia Z; Yan A
Mol Divers; 2017 Aug; 21(3):661-675. PubMed ID: 28484935
[TBL] [Abstract][Full Text] [Related]
15. SAR and QSAR study on the bioactivities of human epidermal growth factor receptor-2 (HER2) inhibitors.
Qu D; Yan A; Zhang JS
SAR QSAR Environ Res; 2017 Feb; 28(2):111-132. PubMed ID: 28235391
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of QSAR Equations for Virtual Screening.
Spiegel J; Senderowitz H
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33105703
[TBL] [Abstract][Full Text] [Related]
17. Classification of HIV-1 Protease Inhibitors by Machine Learning Methods.
Li Y; Tian Y; Qin Z; Yan A
ACS Omega; 2018 Nov; 3(11):15837-15849. PubMed ID: 30556015
[TBL] [Abstract][Full Text] [Related]
18. Drug discovery strategies for novel leukotriene A4 hydrolase inhibitors.
Röhn TA; Numao S; Otto H; Loesche C; Thoma G
Expert Opin Drug Discov; 2021 Dec; 16(12):1483-1495. PubMed ID: 34191664
[TBL] [Abstract][Full Text] [Related]
19. Do we need different machine learning algorithms for QSAR modeling? A comprehensive assessment of 16 machine learning algorithms on 14 QSAR data sets.
Wu Z; Zhu M; Kang Y; Leung EL; Lei T; Shen C; Jiang D; Wang Z; Cao D; Hou T
Brief Bioinform; 2021 Jul; 22(4):. PubMed ID: 33313673
[TBL] [Abstract][Full Text] [Related]
20. SAR and QSAR research on tyrosinase inhibitors using machine learning methods.
Wu Y; Huo D; Chen G; Yan A
SAR QSAR Environ Res; 2021 Feb; 32(2):85-110. PubMed ID: 33517778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
